Unknown

Dataset Information

0

Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study.


ABSTRACT: To determine among patients with autoimmune diseases in the USA whether the risk of non-viral opportunistic infections (OI) was increased among new users of tumour necrosis factor ? inhibitors (TNFI), when compared to users of non-biological agents used for active disease.We identified new users of TNFI among cohorts of rheumatoid arthritis (RA), inflammatory bowel disease and psoriasis-psoriatic arthritis-ankylosing spondylitis patients during 1998-2007 using combined data from Kaiser Permanente Northern California, two pharmaceutical assistance programmes for the elderly, Tennessee Medicaid and US Medicaid/Medicare programmes. We compared incidence of non-viral OI among new TNFI users and patients initiating non-biological disease-modifying antirheumatic drugs (DMARD) overall and within each disease cohort. Cox regression models were used to compare propensity-score and steroid- adjusted OI incidence between new TNFI and non-biological DMARD users.Within a cohort of 33?324 new TNFI users we identified 80 non-viral OI, the most common of which was pneumocystosis (n=16). In the combined cohort, crude rates of non-viral OI among new users of TNFI compared to those initiating non-biological DMARD was 2.7 versus 1.7 per 1000-person-years (aHR 1.6, 95% CI 1.0 to 2.6). Baseline corticosteroid use was associated with non-viral OI (aHR 2.5, 95% CI 1.5 to 4.0). In the RA cohort, rates of non-viral OI among new users of infliximab were higher when compared to patients newly starting non-biological DMARD (aHR 2.6, 95% CI 1.2 to 5.6) or new etanercept users (aHR 2.9, 95% CI 1.5 to 5.4).In the USA, the rate of non-viral OI was higher among new users of TNFI with autoimmune diseases compared to non-biological DMARD users.

SUBMITTER: Baddley JW 

PROVIDER: S-EPMC4273901 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study.

Baddley John W JW   Winthrop Kevin L KL   Chen Lang L   Liu Liyan L   Grijalva Carlos G CG   Delzell Elizabeth E   Beukelman Timothy T   Patkar Nivedita M NM   Xie Fenglong F   Saag Kenneth G KG   Herrinton Lisa J LJ   Solomon Daniel H DH   Lewis James D JD   Curtis Jeffrey R JR  

Annals of the rheumatic diseases 20130713 11


<h4>Objectives</h4>To determine among patients with autoimmune diseases in the USA whether the risk of non-viral opportunistic infections (OI) was increased among new users of tumour necrosis factor α inhibitors (TNFI), when compared to users of non-biological agents used for active disease.<h4>Methods</h4>We identified new users of TNFI among cohorts of rheumatoid arthritis (RA), inflammatory bowel disease and psoriasis-psoriatic arthritis-ankylosing spondylitis patients during 1998-2007 using  ...[more]

Similar Datasets

| S-EPMC8284038 | biostudies-literature
| S-EPMC7496810 | biostudies-literature
| S-EPMC6548222 | biostudies-literature
| S-EPMC3801096 | biostudies-literature
| S-EPMC4408449 | biostudies-literature
| S-EPMC7828521 | biostudies-literature
| S-EPMC4955682 | biostudies-literature
| S-EPMC6043399 | biostudies-literature
| S-EPMC7158940 | biostudies-literature
| S-EPMC7136994 | biostudies-literature